J Korean Cancer Assoc.
1999 Apr;31(2):256-266.
Clinical Relevance of Urokinase-type Plasminogen Activator ( uPA ) , uPA Receptor , Plasminogen Activator Inhibitor-1 Co-expression from Tissue and Serum of Breast Cancer as Targets of Biotherapy
- Affiliations
-
- 1Yonsei Cancer Center
- 2Department of Internal Medicine, Yonsei University College of Medicine, Korea.
- 3Department of General Surgery, Yonsei University College of Medicine, Korea.
- 4Department of Pathology, Yonsei University College of Medicine, Korea.
- 5Department of Internal Medicine, Eulji Medical Center, Seoul, Korea.
Abstract
-
PURPOSE: We measured and compared the uPA, plasminogen activator inhibitor-1 (PAI-1) and uPA receptor (uPAR) levels in breast cancer tissues and blood of the patients to evaluate their clinical relevance for biotherapy.
MATERIALS AND METHODS
uPA, PAI-1 (Monozyme, Netherland), uPAR (American Diagnostics, USA) levels were measured by ELISA assay in 192 breast cancer tissues, in 18 normal breast tissues and in 163 blood from breast cancer patients.
RESULTS
There was a tendency of uPA increment from ductal carcinoma in situ while increment of PAI-1 and uPAR occurred from Ti. With the progression of cancer, uPA, PAI-1, uPAR tended to decrease; however, the uPA/uPAR, uPA/PAI-1 ratios remained unchanged. There was a correlation of uPA expression between normal and cancer tissues ( r(2)= 0.49). Correlation of uPA and PAI-1 was found in normal tissue and stage I cancer tissue while correlation of uPAR and PAI-1 was found with cancer progression. Between cancer tissue and blood significant correlations were found in uPA, PAI-1, uPAR levels.
CONCLUSION
uPA, PAI-1, uPAR levels in cancer tissue elevated from the early stage maintaining correlative expressions with cancer progression. A positive correlation between cancer tissue and blood level suggested the applicability of the levels of uPA, PAI-1 or uPAR for detecting patients for biotherapy.
MeSH Terms
-
Biological Therapy*
Breast Neoplasms*
Breast*
Carcinoma, Intraductal, Noninfiltrating
Enzyme-Linked Immunosorbent Assay
Humans
Plasminogen Activator Inhibitor 1
Plasminogen Activators*
Plasminogen*
Urokinase-Type Plasminogen Activator*
Plasminogen
Plasminogen Activator Inhibitor 1
Plasminogen Activators
Urokinase-Type Plasminogen Activator
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
- Expression of Urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor-1 (PAI-1) in Gallbladder Carcinoma
- Expression of Matrix Metalloproteinase and Urokinase-type Plasminogen Activator in Epithelial Tumors of the Ovary
- Urokinase-type plasminogen activator receptor in IgA nephropathy
- Clinical Significance of Urokinase-type Plasminogen Activator (uPA) Expression from Serum and Tissue of Gastric Cancer Patients
